Figure 5 | Scientific Reports

Figure 5

From: The Toll–Like Receptor 2/6 Agonist, FSL–1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome

Figure 5

FSL–1 drives medullary hematopoiesis. Male C57BL/6 mice were given physiological water (NT) or FSL–1 at 24 hours post TBI. Femurs were collected at days 3, 9, 17 and 31 post TBI (n = 6–15 per group). (a) Representative images of H&E stained femur sections are shown. (b) Quantitative analysis of bone marrow (BM) percent cellularity and (c) BM cell counts per femur are presented. NT, non–radiated and not treated with FSL–1; FSL–1, non–radiated, but treated with FSL–1; TBI, NT, radiated and not treated with FSL–1; TBI, FSL–1, radiated and treated with FSL–1. (d) Representative modified Wright stained cytology images are shown. (e) BM cellular differentiation is represented as ratio of Granulocytic to Erythroid cells (G:E ratio). (f) Representative images of Ki67 stained femur sections are shown. (g) Quantitative analysis of Ki67 positive cells (% of total cells) is summarized from 3 random fields of view. The data includes 713 cells counted for NT samples, 1370 cells counted for FSL–1–treated samples, 858 cells counted for TBI, NT samples and 1979 cells counted for TBI, FSL–1 samples. Data are representative of 3 independent experiments. Graphed data are mean ± s.e.m. **P < 0.01 or ***P < 0.001 between TBI, NT and TBI, FSL–1–treated mice. + P < 0.05, ++ P < 0.01 or ++++ P < 0.0001 between TBI, FSL–1–treated and FSL–1 only treated mice. δ P < 0.05, δδδ P < 0.001 or δδδδ P < 0.0001 between TBI, NT and NT control mice. In c, e and g, each symbol represents one mouse.

Back to article page